NASDAQ:VRTXVertex Pharmaceuticals Competitors & Alternatives

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and Amgen, as reported by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, indicating a potential downside of 2.43%. Amgen has a consensus target price of $246.08, indicating a potential downside of 3.97%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Institutional & Insider Ownership

93.4% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.8% of Amgen shares are held by institutional investors. 0.5% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Amgen on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Vertex Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.com.

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, indicating a potential downside of 2.43%. Gilead Sciences has a consensus target price of $79.6538, indicating a potential upside of 3.77%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Vertex Pharmaceuticals.

Institutional & Insider Ownership

93.4% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 80.2% of Gilead Sciences shares are held by institutional investors. 0.5% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Gilead Sciences on 10 of the 15 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Celgene (NASDAQ:CELG) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Celgene's top-line revenue, earnings per share and valuation.

Celgene has higher revenue and earnings than Vertex Pharmaceuticals. Celgene is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Celgene's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Celgene, as reported by MarketBeat.

Vertex Pharmaceuticals currently has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Celgene has a consensus target price of $105.60, suggesting a potential downside of 2.44%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Celgene.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Celgene has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Institutional and Insider Ownership

93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of Celgene shares are owned by institutional investors. 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Celgene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Celgene on 8 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus target price of $557.7037, suggesting a potential downside of 11.09%. Vertex Pharmaceuticals has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Insider & Institutional Ownership

68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.3% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Biogen and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

87.5% of Biogen shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.5% of Biogen shares are owned by insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Biogen has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Biogen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Biogen presently has a consensus target price of $308.7037, suggesting a potential upside of 16.44%. Vertex Pharmaceuticals has a consensus target price of $284.2308, suggesting a potential downside of 2.43%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Vertex Pharmaceuticals.

Summary

Biogen beats Vertex Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seattle Genetics (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

94.3% of Seattle Genetics shares are owned by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. 31.1% of Seattle Genetics shares are owned by company insiders. Comparatively, 0.5% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Seattle Genetics and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Seattle Genetics and Vertex Pharmaceuticals, as provided by MarketBeat.

Seattle Genetics presently has a consensus price target of $148.2778, suggesting a potential downside of 13.01%. Vertex Pharmaceuticals has a consensus price target of $284.2308, suggesting a potential downside of 2.43%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seattle Genetics.

Profitability

This table compares Seattle Genetics and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Seattle Genetics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Seattle Genetics on 10 of the 14 factors compared between the two stocks.